Real-world therapeutic benefits of patients on insulin glargine versus NPH insulin
Crossref DOI link: https://doi.org/10.1007/s00592-016-0862-0
Published Online: 2016-04-19
Published Print: 2016-10
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Fiesselmann, Albrecht
Wiesner, Tobias
Fleischmann, Holger
Bramlage, Peter
Funding for this research was provided by:
Sanofi- Aventis GmbH, Berlin, Germany
Text and Data Mining valid from 2016-04-19